PCAT1 and prostate carcinoma: Furthermore, a prostate cancer risk-associated variant at rs7463708 has been shown to increase binding of a recently identified androgen receptor (AR)-interacting transcription factor, at a distal enhancer that loops to the PCAT-1 promoter, which leads to over-expression of PCAT-1following continued androgen treatment.